שם החברה: Immune System Key (ISK) Ltd

שנת ייסוד: 2005

מספר עובדים:

סקטור: Life sciences

תת סקטור: Biotechnology

פרופיל חברה

Immune System Key Ltd. (ISK) was established in June 2005 as a Jerusalem-based privately held company engaged in drug development. Its assets include nerofe'™ a novel protein capable of treating cancer and the immune disorders. The company’s vision is to develop new therapeutic drugs that can distinguish between cancer or inflamed cells and healthy cells and induce programmed cell death in cancer and inflamed cells only. Over the next two years, Immune System Key will establish initial safety and pharmacological profiles. The company’s goal is to raise funds in order to complete pre-clinical trials for nerofe'™ derivatives as drug candidates for treatment of Breast Cancer, Lung Cancer, Glioblastoma and for Crohn’s Disease and Ulcerative Colitis, as well as to establish proof-of-concept and therapeutic potential for diabetes and rheumatoid arthritis in animal models.